Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tiziana Partners with Renaissance Lakewood to Scale Up Foralumab | Contract Pharma
Breaking News

Tiziana Partners with Renaissance Lakewood to Scale Up Foralumab

Renaissance will optimize the formulation of intranasal Foralumab and assist with scaling up production for clinical trials.

Tiziana Life Sciences Ltd., a clinical-stage biotechnology company, entered an agreement with Renaissance Lakewood LLC, a CDMO, to advance the development intra-nasal drug candidate Foralumab.

Foralumab, a biologic drug candidate, is Tiziana’s fully human anti-CD3 monoclonal antibody in development for neurodegenerative and inflammatory diseases.

Under the agreement, Renaissance will use its expertise in nasal drug delivery to optimize the formulation of intranasal Foralumab and assist with scaling up production for clinical trials.
Tiziana is working to expediting the clinical development of Foralumab, particularly for conditions like Alzheimer’s disease and multiple sclerosis, where neuroinflammation plays a significant role in disease progression.

Intranasal foralumab has shown promising potential in early clinical studies, including significant improvements in immune modulation by activating T regulatory cells that cross the blood-brain barrier, offering a novel treatment approach for neuroinflammatory and neurodegenerative diseases.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters